Acrivon Posts Narrower Loss in Q2

Acrivon Therapeutics (NASDAQ:ACRV), a clinical-stage biotech developing precision oncology medicines, released its second quarter 2025 results on August 13, 2025. The report showed a GAAP net loss per share of $(0.55), beating estimates by $0.02 (GAAP EPS: -$0.55 vs. estimate: -$0.57). The company once again delivered no revenue, consistent with its pre-commercial stage, and saw operating losses (GAAP) widen compared to the same period last year. Expenses climbed modestly year over year as Acrivon advanced key clinical programs, with research and development expenses (GAAP) rising to $16.2 million from $15.0 million in Q2 2024. Overall, the quarter tracked with expectations for a late-stage biotech prioritizing data generation and platform advancement ahead of future regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Acrivon Therapeutics focuses on developing targeted cancer therapies using its proprietary AP3 platform, which is a proteomics-based technology. The AP3 platform analyzes proteins inside tumor cells to predict which patients are most likely to benefit from Acrivon's drugs. This precision-medicine approach differs from traditional drug development by moving beyond genetic testing and seeking to capture real-time biological pathways active within each patient’s tumor.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool